TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens

PHASE3CompletedINTERVENTIONAL
Enrollment

2,516

Participants

Timeline

Start Date

January 25, 2016

Primary Completion Date

July 31, 2020

Study Completion Date

May 31, 2021

Conditions
Tuberculosis
Interventions
DRUG

rifapentine

Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment

DRUG

rifapentine and moxifloxacin

Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.

DRUG

control

standard six-month treatment

Trial Locations (33)

263

TBTC Site 41/ ACTG Site 30313 Parirenyatwa Clinical Research Site, Harare

1864

TBTC Site 34 Wits Health Consortium Perinatal HIV Research Unit (PHRU), Soweto

2013

TBTC Site 49/ ACTG Site 12301 Soweto ACTG CRS, Soweto

2092

TBTC Site 07/ ACTG Site 11101 Wits Helen Joseph CRS, Johannesburg

4093

TBTC Site 06/ ACTG Site 11201 Durban International Clinical Research Site, Durban

7505

TBTC Site 01/ACTG Site 8950 FAM CRU, Parow Valley

7530

TBTC Site 10/ ACTG Site 31718 TASK Applied Science, Bellville

7700

TBTC Site 09/ ACTG Site 31792 University of Cape Town Lung Institute (Pty) Ltd, Mowbray

7705

TBTC Site 08/ ACTG Site 31793 South African Tuberculosis Vaccine Initiative (SATVI), Cape Town

10000

TBTC Site 37 Vietnam NTP/UCSF Research Collaboration, Hanoi

10032

TBTC Site 24 Columbia Unversity, New York

10330

TBTC Site 42/ ACTG Site 31802 The Thai Red Cross AIDS Research Centre, Pathumwan

20200

TBTC Site 02/ ACTG 12501 Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS, Kericho

30100

TBTC Site 03/ ACTG Site 12601 Moi University Clinical Research Site, Eldoret

40100

TBTC Site 39/ ACTG Site 31460 Kisumu CRS, Kisumu

50200

TBTC Site 69/ ACTG Site 31784 Thai-CTIU, CMU HIV Treatment CRS, Muang Chiang Mai

76104

TBTC Site 20 UNTHSC (University of North Texas Health Science Center), Fort Worth

77030

TBTC Site 62 Baylor College of Medicine & Affiliated Hospitals/VA, Houston

94110

TBTC Site 82/ ACTG Site 801 USCF AIDS CRS, San Francisco

600113

TBTC Site 44/ ACTG Site 11701 CART CRS, YRGCARE Medical Centre VHS, Chennai

4110011

TBTC Site 43/ ACTG Site 31441 BJ Medical College, Pune

78229-4404

TBTC Site 63 San Antonio VA Medical Center (South Texas Group), San Antonio

91350-200

TBTC Site 94/ ACTG Site 12201 Hospital Nossa Senhora da Conceicao, Porto Alegre

21040-360

TBTC Site 91/ ACTG Site 12101 Insituto Nacional de Pesquisa Clínica Evandro Chagas, Rio de Janeiro

Unknown

TBTC Site 36 TB and Chest Service of Hong Kong, China, Hong Kong

TBTC Site 04/ ACTG Site 30301 Blantyre CRS (or College of Medicine - Johns Hopkins Research Project, COM-JHP), Blantyre

TBTC Site 05/ ACTG Site 12001 UNC Project Tidziwe Centre, Lilongwe

TBTC Site 11/ ACTG Site 12401 Joint Clinical Research Centre, Kampala Clinical Research Site, Kampala

TBTC Site 30 Uganda-Case Western Reserve Research Collaboration, Kampala

HT 6124

TBTC Site 67/ ACTG Site 31730 GHESKIO centers IMIS, Port-au-Prince

HT6110

TBTC Site 45/ ACTG Site 30022: Les Centres Gheskio (INLR), Port-au-Prince

Lima 04

TBTC Site 90/ ACTG Site 11301 Asociacion Civil Impacta Salud y Educacion, Lima

Lima 32

TBTC Site 93/ ACTG Site 11302 CRS San Miguel, Lima

All Listed Sponsors
collaborator

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

NETWORK

lead

Centers for Disease Control and Prevention

FED

NCT02410772 - TBTC Study 31: Rifapentine-containing Tuberculosis Treatment Shortening Regimens | Biotech Hunter | Biotech Hunter